| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
|
J Clin Oncol
|
2008
|
2.44
|
|
2
|
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
|
Sci Transl Med
|
2012
|
2.22
|
|
3
|
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.
|
J Clin Oncol
|
2010
|
2.20
|
|
4
|
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.91
|
|
5
|
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
|
Blood
|
2005
|
1.89
|
|
6
|
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
|
Biol Blood Marrow Transplant
|
2008
|
1.69
|
|
7
|
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.
|
J Clin Oncol
|
2013
|
1.67
|
|
8
|
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2011
|
1.62
|
|
9
|
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
|
Br J Haematol
|
2009
|
1.57
|
|
10
|
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2011
|
1.46
|
|
11
|
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
|
Leuk Lymphoma
|
2012
|
1.45
|
|
12
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
13
|
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.27
|
|
14
|
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
|
Blood
|
2012
|
1.15
|
|
15
|
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.
|
Clin Cancer Res
|
2013
|
1.15
|
|
16
|
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.
|
Blood
|
2004
|
1.13
|
|
17
|
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2013
|
1.12
|
|
18
|
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.
|
Br J Haematol
|
2008
|
1.09
|
|
19
|
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
20
|
Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
|
Biol Blood Marrow Transplant
|
2007
|
1.07
|
|
21
|
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
|
Br J Haematol
|
2009
|
1.07
|
|
22
|
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.
|
Cancer Discov
|
2011
|
1.02
|
|
23
|
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
|
Biol Blood Marrow Transplant
|
2007
|
1.02
|
|
24
|
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
|
Br J Haematol
|
2012
|
1.00
|
|
25
|
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
|
Cancer
|
2003
|
0.97
|
|
26
|
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.93
|
|
27
|
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
|
J Infect Dis
|
2013
|
0.92
|
|
28
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Cancer Cell
|
2016
|
0.87
|
|
29
|
Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma.
|
J Clin Oncol
|
2004
|
0.85
|
|
30
|
Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery.
|
J Clin Oncol
|
2011
|
0.84
|
|
31
|
Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.83
|
|
32
|
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
|
Leuk Res
|
2004
|
0.83
|
|
33
|
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
|
Haematologica
|
2012
|
0.83
|
|
34
|
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.83
|
|
35
|
Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma.
|
J Clin Oncol
|
2012
|
0.82
|
|
36
|
Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.79
|
|
37
|
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2004
|
0.79
|
|
38
|
Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation.
|
Leuk Lymphoma
|
2014
|
0.78
|
|
39
|
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
40
|
Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
|
Leuk Lymphoma
|
2010
|
0.77
|
|
41
|
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Haematologica
|
2013
|
0.76
|
|
42
|
Challenging manifestations of malignancies. Case 2. Langerhans cell histiocytosis presenting with a skin rash.
|
J Clin Oncol
|
2004
|
0.75
|
|
43
|
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
44
|
Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
|
Biol Blood Marrow Transplant
|
2002
|
0.75
|
|
45
|
Lyme meningoradiculitis and myositis after allogeneic hematopoietic stem cell transplantation.
|
Clin Infect Dis
|
2005
|
0.75
|
|
46
|
Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir.
|
JAMA Dermatol
|
2013
|
0.75
|